Merck
Also known as: Dey LP | Dey, L.P. | Dey Pharma, L.P. | Fulford India Limited | LLC Merck, Russia | MERCK | Merck A.B., Sweden | Merck A.E., Greece | MERCK AND CO INC | Merck A/S, Denmark | Merck B.V., Netherlands | Merck Canada Inc | Merck Canada Inc. | Merck & Cie | Merck Frosst Canada Ltd. | Merck Frosst-Schering Pharma, G.P. | Merck Gesellschaft mbH, Austria | Merck Inc., Philippines | Merck Institute for Therapeutic Research | Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Merck Ltd. | Merck Ltd., India | Merck Ltd., Taiwan | Merck N.V.-S.A., Belgium | Merck OY, Finland | Merck/Pfizer | Merck Pharma, K.S., Slovakia | Merck Pte. Ltd., Singapore | Merck (Pvt.) Limited, Pakistan | Merck Pvt. Ltd, Pakistan | Merck S.A. de C.V., Mexico | Merck Sante S.A.S. France | Merck, S.A., Portugal | Merck Schering-Plough | Merck Sharp and Dohme LLC | Merck Sharp and Dohme, LLC | MERCK SHARP AND DOHME LLC | MERCK SHARP DOHME | Merck Sharp & Dohme (Australia) Pty Limited | Merck Sharp & Dohme (Australia) Pty Ltd | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme LLC | Merck Sharp & Dohme Ltd | Merck Sharp & Dohme (MSD) | Merck, Sharpe & Dohme Corp. | Merck Sharpe & Dohme LLC | Merck Shering-Plough JV Study | Merck, S.L., Spain | Merck spol.s.r.o., Czech Republic | Merck spol. s r.o., Slovakia | Merck SP. Z.O.O., Poland | Merck Women's Health Investigator Initiated Studies Program | Merk Sharp & Dohme España S.A. | MSD | MSD Belgium BVBA | MSD France | MSD INTL | MSD INTL GMBH | MSD K.K. | MSD Korea Ltd. | MSD MERCK CO | MSD Pharmaceuticals LLC | MSD SHARP and DOHME GMBH Haar Germany | MSD SHARP & DOHME GmbH (formerly Essex Pharma GmbH) | MSD Sharp & Dohme GmbH, Germany | MSD SUB MERCK | MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. | MSI | MSP Vaccine Company | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Raltegravir is provided by Merck. | STRATEGIC ALLIANCE: Merck | TeleRx | VESTAL LABS | Vlaams Instituut voor Biotechnologie (VIB); Merck Sharp & Dohme (MSD)
Highest phase reached
Phase 4
First clinical trial
Sep 1, 1983First marketed drug
Oct 1, 1925First NDA
Oct 1, 1925Last known activity
Jul 1, 2026
Timeline
1910s
- Jan 1, 1917
Merck— Founded
1920s
- Jan 1, 1927
Power-Weightman— Acquired
- Jun 1, 1927
Powers & Weightman— Acquired
- Jan 1, 1929
H.K. Mulford Company— Acquired
1950s
- Jan 1, 1953
Sharp & Dohme— Acquired
1960s
- Jan 1, 1965
Charles E. Frosst Ltd— Acquired
- Apr 7, 1967
thiabendazole— NDA Organization
- Jan 1, 1969
Chibret Laboratories— Acquired
1970s
- Apr 18, 1975
hydroxocobalamin— Marketing Organization
1980s
- Jan 1, 1980
Inter-X— Acquired
1990s
- Jan 1, 1993
Medco Containment Services Inc— Acquired
2000s
- Jan 1, 2004
Banyu Pharmaceutical— Acquired
- Jan 1, 2006
Sirna Therapeutics— Acquired
- Jun 1, 2006
GlycoFi— Acquired
- Jan 1, 2007
NovaCardia— Acquired
- Jan 1, 2009
Insmed, Inc.— Acquired - Jan 1, 2009
Schering-Plough— Acquired
2010s
- Jan 1, 2010
SmartCells— Acquired
- Jan 1, 2011
Inspire Pharmaceuticals— Acquired
- Jun 1, 2011
Hawaii Biotech— Acquired
- Apr 8, 2013
Sentrx— Acquired
- Jan 1, 2014
Idenix— Acquired
- Dec 8, 2014
Cubist— Acquired
- Jan 1, 2015
cCam Biotherapeutics— Acquired
- Jan 1, 2015
Harrisvaccines— Acquired
- Jan 1, 2015
OncoEthix— Acquired
- Jan 11, 2016
IOmet Pharma— Acquired
- Jun 9, 2016
Afferent Pharmaceuticals— Acquired
- Sep 6, 2017
Rigontec GMBH— Acquired
- Oct 10, 2017
KalVista Pharmaceuticals, Ltd.— Acquired
- Feb 21, 2018
Viralytics— Acquired
- Feb 21, 2019
Immune Design— Acquired
- May 21, 2019
Peloton Therapeutics, Inc.— Acquired
- Jun 10, 2019
Tilos Therapeutics— Acquired
- Dec 9, 2019
ArQule— Acquired
2020s
- May 26, 2020
Themis Bioscience GmbH— Acquired
- Nov 5, 2020
VelosBio— Acquired
- Nov 23, 2020
OncoImmune, Inc.— Acquired
- Feb 24, 2021
Pandion Therapeutics— Acquired
- Aug 13, 2021
Belzutifan— NDA Secondary Org
- Sep 30, 2021
Acceleron Pharma, Inc.— Acquired
- Nov 21, 2022
Imago BioSciences— Acquired
- Apr 17, 2023
Prometheus Inc.— Acquired
- Jan 8, 2024
Harpoon Therapeutics— Acquired
- May 29, 2024
EyeBiotech Ltd.— Acquired
- Jul 9, 2025
Verona Pharma plc— Acquired
- Nov 19, 2025
Cidara Therapeutics— Acquired
Drugs by trial phase (1217 distinct, 4505 trials)
Phase 4 (153 own, 93 via acquisition)
Phase 3 (200 own, 95 via acquisition)
Phase 2 (305 own, 79 via acquisition)
Phase 1 (225 own, 51 via acquisition)
Indications
Approved for
- Abdominal Abscess
- Actinomycosis
- Acute Coronary Syndrome
- Acute Pain
- Addison Disease
- Adenocarcinoma
- Adenomatous Polyposis Coli
- Adrenal Hyperplasia, Congenital
- Adrenal Insufficiency
- Alopecia
- Anaphylaxis
- Anemia, Aplastic
- Anemia, Hemolytic
- Angioedema
- Anthrax
- Arrhythmias, Cardiac
- Arthritis
- Arthritis, Gouty
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Asthma, Exercise-Induced
- Atherosclerosis
- Bacterial Infections
- Botulism
- Brain Edema
- Bronchoconstriction
- Bursitis
- Candidemia
- Candidiasis
- Carcinoma
- Cardiovascular Diseases
- Chorioretinitis
- Choroiditis
- Chronic Urticaria
- Colitis, Ulcerative
- Conjunctivitis
- Conjunctivitis, Allergic
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Cystinuria
- Cytomegalovirus Infections
- Depression
- Dermatitis, Atopic
- Dermatitis, Contact
- Dermatitis, Exfoliative
- Dermatitis Herpetiformis
- Dermatitis, Seborrheic
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diphtheria
- Dyslipidemias
- Eczema
- Endocarditis
- Endocarditis, Bacterial
- Erythema Multiforme
- Escherichia coli Infections
- Esotropia
- Familial Mediterranean Fever
- Gestational Trophoblastic Disease
- Glaucoma
- Glaucoma, Open-Angle
- Gonorrhea
- Gout
- Heart Failure
- Helicobacter pylori
- Hemorrhage
- Hepatitis C
- Hepatitis C, Chronic
- Hepatolenticular Degeneration
- Herpes Zoster Ophthalmicus
- HIV Infections
- Hodgkin Disease
- Hypercalcemia
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemia Type II
- Hypersensitivity
- Hypertension
- Hypoglycemia
- Hypokalemic Periodic Paralysis
- Ichthyosis
- Infections
- Inflammation
- Intraabdominal Infections
- Invasive Pulmonary Aspergillosis
- Iridocyclitis
- Iritis
- Keratitis
- Keratosis
- Kidney Diseases
- Larva Migrans
- Larva Migrans, Visceral
- Laryngeal Edema
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Studied for
- Abdominal Injuries
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Acute Pain
- Adenocarcinoma
- Adenocarcinoma in Situ
- Adenocarcinoma of Lung
- Adenoma
- Adenomatous Polyposis Coli
- Adenoviridae Infections
- Adrenocortical Carcinoma
- Aggression
- Akathisia, Drug-Induced
- Alcoholism
- Alopecia
- Alopecia Areata
- Alzheimer Disease
- Anaphylaxis
- Anemia
- Anemia, Aplastic
- Anemia, Sickle Cell
- Angina Pectoris
- Angina, Stable
- Ankle Injuries
- Anus Neoplasms
- Anxiety Disorders
- Aortic Dissection
- Aortic Valve Stenosis
- Apnea
- Appendicitis
- Arachnodactyly
- Arterial Occlusive Diseases
- Arteriosclerosis
- Arteriovenous Fistula
- Arthritis
- Arthritis, Gouty
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Aspergillosis
- Asthma
- Asthma, Exercise-Induced
- Astrocytoma
- Atherosclerosis
- Atrial Fibrillation
- Atrial Flutter
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Autoimmune Diseases
- Back Pain
- Bacteremia
- Bacterial Infections
- Basal Cell Carcinoma
- Bile Duct Diseases
- Bile Duct Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Bipolar Disorder
- Birth Weight
- Blast Crisis
- Blepharitis
- Body Weight
- Bone Diseases
- Bone Diseases, Metabolic
- Bone Marrow Diseases
- Bone Neoplasms
- Brain Diseases
- Brain Neoplasms
- Breast Diseases
- Breast Neoplasms
- Breast Neoplasms, Male
- Bronchial Neoplasms
- Bronchial Spasm
- Bronchiolitis
- Bronchitis
- Bronchitis, Chronic
- Bronchopulmonary Dysplasia
- Burns
- Bursitis
- Cancer Pain
- Candidiasis
- Candidiasis, Invasive
- Candidiasis, Oral
- Candidiasis, Vulvovaginal
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Adenoid Cystic
- Carcinoma, Endometrioid
- Carcinoma, Hepatocellular
- Carcinoma in Situ
- Carcinoma, Large Cell
- Carcinoma, Medullary
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
Marketed drugs (132)
Subsidiaries (43 direct, 78 total across the full acquisition tree)
- Acceleron Pharma, Inc.
- Afferent Pharmaceuticals
- ArQule
- Banyu Pharmaceutical
- cCam Biotherapeutics
- Charles E. Frosst Ltd
- Chibret Laboratories
- Cidara Therapeutics
- Cubist
- EyeBiotech Ltd.
- GlycoFi
- Harpoon Therapeutics
- Harrisvaccines
- Hawaii Biotech
- H.K. Mulford Company
- Idenix
- Imago BioSciences
- Immune Design
- Insmed, Inc.
- Inspire Pharmaceuticals
- Inter-X
- IOmet Pharma
- KalVista Pharmaceuticals, Ltd.
- Medco Containment Services Inc
- NovaCardia
- OncoEthix
- OncoImmune, Inc.
- Pandion Therapeutics
- Peloton Therapeutics, Inc.
- Powers & Weightman
- Power-Weightman
- Prometheus Inc.
- Rigontec GMBH
- Schering-Plough
- Sentrx
- Sharp & Dohme
- Sirna Therapeutics
- SmartCells
- Themis Bioscience GmbH
- Tilos Therapeutics
- VelosBio
- Verona Pharma plc
- Viralytics
- Adolor Corp L2
- Calixa L2
- Camitro L2
- Canji L2
- Carbylan Therapeutics, Inc. L2
- Cyclis Pharmaceuticals L2
- DNAX L2
- Faro Pharmaceuticals L2
- Farr and Kunzi L2
- Illumigen Biosciences L2
- Koninklijke Zwanenberg Organon L2
- NeoGenesis Pharmaceuticals L2
- Optimer Pharmaceuticals L2
- Organon L2
- Plough L2
- Rosengarten & Sons, Inc. L2
- Schering L2
- TerraGen Discovery L2
- Transave Inc. L2
- Triton Biosciences L2
- Trius Therapeutics L2
- Forendo Pharma Ltd L3
- Koninklijke Zout Organon L3
- Kortman and Schulte L3
- Maybelline Company L3
- Nobilon International BV L3
- Noury & Van der Lande L3
- Scholl Manufacturing L3
- St Joseph Company L3
- White Laboratories L3
- Zwanenburg L3
- Koninklijke Zout Ketjen L4
- Ketjen L5
- Koninklijke Nederlandse Zoutindustrie L5
- Sikkens Lakken L5
Recent trials (50)
- NCT07266519CollaboratorPhase 2Jul 1, 2026
- NCT07267338CollaboratorPhase 2Jun 30, 2026
- NCT07187778CollaboratorPhase 2Feb 28, 2026
- NCT07302347Lead sponsorPhase 1/Phase 2Feb 20, 2026
- NCT07302347OfficialPhase 1/Phase 2Feb 20, 2026
- NCT07286149Lead sponsorPhase 1/Phase 2Feb 9, 2026
- NCT07286149OfficialPhase 1/Phase 2Feb 9, 2026
- NCT07300267Lead sponsorPhase 1Jan 21, 2026
- NCT07300267OfficialPhase 1Jan 21, 2026
- NCT07252739OfficialPhase 2Jan 14, 2026
- NCT07252739Lead sponsorPhase 2Jan 14, 2026
- NCT07305831Lead sponsorPhase 1Jan 13, 2026
- NCT07305831OfficialPhase 1Jan 13, 2026
- NCT07244393CollaboratorPhase 1Dec 31, 2025
- NCT07276880CollaboratorPhase 2Dec 31, 2025
Details
- Founded
- New York, NY, US Jan 1, 1917
- First NDA
- Oct 1, 1925
- Last known activity
- Jul 1, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval